Search results
Results from the WOW.Com Content Network
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. [3] This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. [3] It is used by injection into a vein. [3] Side effects generally occur. [3]
1) Platinum-based compounds, namely oxaliplatin, cisplatin, and carboplatin (which is noticeably less neurotoxic than cisplatin), are used to treat several types of solid tumors, such as stomach, liver, lung, ovarian, brain, and uterine cancers. [3] These agents can damage dorsal root ganglia neurons by forming adducts with nuclear and ...
Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. [37] [38] They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. [41] Non-classical alkylating agents include procarbazine and hexamethylmelamine. [37] [38]
cisplatin, etoposide, bleomycin: non-seminomatous germ cell tumors PEI cisplatin, etoposide, ifosfamide: small-cell lung carcinoma platin + taxane [5] cisplatin/carboplatin, paclitaxel/docetaxel: ovarian cancer: POMP 6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone: acute adult leukemia [6] ProMACE-MOPP
Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. [ 1 ]